MoneyWorks4Me

Biocon submits copy of press release

24 Dec 2015 Evaluate

Biocon has submitted a copy of Press Release dated December 24, 2015, titled ‘Biocon Introduces CIMIVIR-L for Hepatitis-C in India’.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

397.35 -4.65 (-1.16%)
04-Sep-2026 15:03 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1901.60
Dr. Reddys Labs. 1156.05
Cipla 1378.00
Lupin 2104.60
Zydus Lifesciences 1125.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: